Xilio Therapeutics, Inc. (XLO)Healthcare | Biotechnology | Waltham, United States | NasdaqCM
8.57 USD
+0.22
(2.635%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.74 +0.17 (1.984%) ⇧ (April 17, 2026, 5:52 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:33 p.m. EDT
High short-term risk despite a recent speculative upgrade due to a crushing -5.98% directional forecast and a distressed reversal split situation; fundamentally unattractive long-term due to -80% profit margins, only $137M cash versus 2026 trial start timeline, and no earnings visibility. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.069594 |
| MSTL | 0.089565 |
| AutoARIMA | 0.094999 |
| AutoETS | 0.095001 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 66% |
| H-stat | 1.54 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.136 |
| Excess Kurtosis | -0.80 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.715 |
| Revenue per Share | 9.66 |
| Market Cap | 49,556,116 |
| Forward P/E | -14.78 |
| Beta | -0.12 |
| Profit Margins | -80.05% |
| Website | https://xiliotx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.24890447 |
| Address1 | 828 Winter Street |
| Address2 | Suite 300 |
| All Time High | 391.3 |
| All Time Low | 6.468 |
| Ask | 10.72 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 28,920 |
| Average Daily Volume3 Month | 39,658 |
| Average Volume | 39,658 |
| Average Volume10Days | 28,920 |
| Beta | -0.12 |
| Bid | 6.12 |
| Bid Size | 2 |
| Book Value | 7.785 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.57 |
| Current Ratio | 2.577 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.76 |
| Day Low | 8.31 |
| Debt To Equity | 19.715 |
| Display Name | Xilio Therapeutics |
| Earnings Timestamp End | 1,754,911,858 |
| Earnings Timestamp Start | 1,754,479,858 |
| Ebitda | -40,441,000 |
| Ebitda Margins | -0.92403 |
| Enterprise To Ebitda | 2.003 |
| Enterprise To Revenue | -1.851 |
| Enterprise Value | -81,020,880 |
| Eps Forward | -0.58 |
| Eps Trailing Twelve Months | -4.19 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.93634 |
| Fifty Day Average Change | 0.63365984 |
| Fifty Day Average Change Percent | 0.07984283 |
| Fifty Two Week Change Percent | -24.890446 |
| Fifty Two Week High | 16.52 |
| Fifty Two Week High Change | -7.950001 |
| Fifty Two Week High Change Percent | -0.4812349 |
| Fifty Two Week Low | 6.468 |
| Fifty Two Week Low Change | 2.1019998 |
| Fifty Two Week Low Change Percent | 0.3249845 |
| Fifty Two Week Range | 6.468 - 16.52 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,634,909,400,000 |
| Float Shares | 3,446,377 |
| Forward Eps | -0.58 |
| Forward P E | -14.775862 |
| Free Cashflow | 8,027,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 76 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 43,766,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.29479998 |
| Held Percent Institutions | 0.35394 |
| Implied Shares Outstanding | 5,782,511 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-22 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,773,619,200 |
| Last Split Factor | 1:14 |
| Long Business Summary | Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. |
| Long Name | Xilio Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 49,556,116 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_365333564 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -35,036,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 49,556,119 |
| Number Of Analyst Opinions | 1 |
| Open | 8.61 |
| Operating Cashflow | -4,992,000 |
| Operating Margins | -0.86483 |
| Payout Ratio | 0.0 |
| Phone | 857 524 2466 |
| Post Market Change | 0.17000008 |
| Post Market Change Percent | 1.9836649 |
| Post Market Price | 8.74 |
| Post Market Time | 1,776,462,748 |
| Previous Close | 8.35 |
| Price Hint | 2 |
| Price To Book | 1.100835 |
| Price To Sales Trailing12 Months | 1.1322972 |
| Profit Margins | -0.80053 |
| Quick Ratio | 2.533 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.219999 |
| Regular Market Change Percent | 2.63472 |
| Regular Market Day High | 8.76 |
| Regular Market Day Low | 8.31 |
| Regular Market Day Range | 8.31 - 8.76 |
| Regular Market Open | 8.61 |
| Regular Market Previous Close | 8.35 |
| Regular Market Price | 8.57 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 40,360 |
| Return On Assets | -0.23245001 |
| Return On Equity | -1.3253399 |
| Revenue Growth | 6.939 |
| Revenue Per Share | 9.66 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 5,782,511 |
| Shares Percent Shares Out | 0.031600002 |
| Shares Short | 182,492 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 150,981 |
| Short Name | Xilio Therapeutics, Inc. |
| Short Percent Of Float | 0.0397 |
| Short Ratio | 3.8 |
| Source Interval | 15 |
| State | MA |
| Symbol | XLO |
| Target High Price | 20.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 20.0 |
| Target Median Price | 20.0 |
| Total Cash | 137,531,008 |
| Total Cash Per Share | 23.784 |
| Total Debt | 6,954,000 |
| Total Revenue | 43,766,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.19 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.525535 |
| Two Hundred Day Average Change | -0.95553493 |
| Two Hundred Day Average Change Percent | -0.100313 |
| Type Disp | Equity |
| Volume | 40,360 |
| Website | https://xiliotx.com |
| Zip | 2,451 |